Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological variables associated to immune checkpoint inhibitor toxicity in cancer patients
2021-000027-12Phase 2Active
- Sponsor
- Institut Jules Bordet
- Start
- May 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of atezolizumab, avelumab, axitinib, bevacizumab, cabozantinib and 12 more in Nonhematologic neoplasms, sponsored by Institut Jules Bordet. Started May 2022; status: active.
02
Drugs
atezolizumabavelumabaxitinibbevacizumabcabozantinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2021-000027-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000027-12.